F, B., V, R., E, G., P, O., J, S., P, M., . . . G, M. (2025). Combined plasma levels of A-type-natriuretic peptide and adrenomedullin are associated with appropriate anti-arrhythmia therapy in patients with an implantable cardioverter defibrillator but no prior device therapy. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 30(5), 371. https://doi.org/10.1080/1354750X.2025.2553630
Chicago Style (17th ed.) CitationF, Beygui, et al. "Combined Plasma Levels of A-type-natriuretic Peptide and Adrenomedullin Are Associated with Appropriate Anti-arrhythmia Therapy in Patients with an Implantable Cardioverter Defibrillator but No Prior Device Therapy." Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals 30, no. 5 (2025): 371. https://doi.org/10.1080/1354750X.2025.2553630.
MLA (9th ed.) CitationF, Beygui, et al. "Combined Plasma Levels of A-type-natriuretic Peptide and Adrenomedullin Are Associated with Appropriate Anti-arrhythmia Therapy in Patients with an Implantable Cardioverter Defibrillator but No Prior Device Therapy." Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals, vol. 30, no. 5, 2025, p. 371, https://doi.org/10.1080/1354750X.2025.2553630.
